Kexin Xu

Kexin Xu
About Kexin Xu

The first medical treatment for metastatic prostate cancer is Androgen Deprivation Therapy (ADT). Unfortunately, nearly 100% of patients become refractory to this treatment and their cancer progresses to androgen-independent of castration-resistant stage (CRPC). A critical understanding of the biochemical mechanisms underlying castration resistance is important and may lead to the discovery and delivery of new treatments for patients with this potentially lethal form of prostate cancer. Dr. Kexin Xu is assessing the function of one protein, EZH2 that has been implicated in previous studies to play a critical role in the development of castration-resistant prostate cancer. Findings from the research will provide information on mechanisms underlying progression of prostate cancer to a state of castration resistance. This knowledge will guide the discovery of more effective and targeted therapies for advanced, metastatic prostate cancer.


The 2011 Progenics Dr. Stephen Morris – PCF Young Investigator Award

Kexin Xu, PhD

Dana-Farber Cancer Institute, Harvard University


Myles Brown, MD